drugset / Trial / NCT00617513

Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation

NCT00617513

Phase 2 Completed 174 enrolled Movetis
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine which dose of prucalopride is safe and effective in patients with chronic idiopathic constipation. Hypothesis: Prucalopride 1 and 2 mg are safe and effective for the treatment of chronic idiopathic constipation whereas 0,5 mg is a suboptimal dose.

Timeline

Start
1995-03
Primary completion
1996-03
Completion
1996-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prucalopride Small molecule 0.5 mg Oral
Comparator Prucalopride Small molecule 1 mg Oral
Comparator Prucalopride Small molecule 2 mg Oral

Indications